Policy expert pushes for ban on off-label prescribing of psychoactive drugs

07/5/2011 | Forbes

Cases of drugmakers' settling off-label marketing cases has prompted calls to prohibit prescribing of psychoactive drugs for nonindicated uses. A rise in diagnoses of certain mental disorders, especially in children, has paralleled a philosophical shift from psychotherapy to medication and reflects doctors', drugmakers' and some Medicaid recipients' financial stakes in psychoactive drugs, says Marcia Angell, a senior lecturer in social medicine at Harvard Medical School and former editor-in-chief of the New England Journal of Medicine.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA